Abstract: The present invention relates to canine amniotic membrane-derived multipotent stem cells (cAM-MSCs) and preparation method thereof. More particularly, the present invention relates to canine amniotic membrane-derived multipotent stem cells, which show negative immunological properties on human markers CD3, CD11c, CD28, CD34, CD38, CD41a, CD45, and CD62L and positive immunological properties on human markers CD90 and CD105, and have the ability to be maintained in an undifferentiated state for 20 passages or more and the ability to be differentiated into fat, bones, nerves, cartilage, etc.
Type:
Grant
Filed:
December 6, 2012
Date of Patent:
September 26, 2017
Assignee:
KANG STEM BIOTECH, CO., LTD.
Inventors:
Kyung Sun Kang, Min Soo Seo, Sang Bum Park
Abstract: The present invention relates to equine amniotic membrane-derived mesenchymal stem cells (eAM-MSCs) and a preparation method thereof. More specifically, the present invention relates to equine amniotic membrane-derived mesenchymal stem cells, which show negative immunological responses to all of the human markers CD19, CD20, CD28, CD31, CD34, CD38, CD41a, CD62L, CD62P and CD200, and positive immunological responses to all of the human markers CD44, CD90 and CD105, and have the ability to be maintained in an undifferentiated state for 14 passages or more and the ability to differentiate into ectoderm, mesoderm and endoderm-derived cells.
Type:
Grant
Filed:
November 22, 2012
Date of Patent:
May 16, 2017
Assignee:
Kang Stem Biotech, Co., LTD.
Inventors:
Kyung Sun Kang, Min Soo Seo, Sang Bum Park
Abstract: The present invention relates to a pharmaceutical composition for the prevention or treatment of immune disorders and inflammatory diseases, comprising stem cells that are generated by culturing stem cells expression Nucleotide-binding Oligomerization Domain protein 2 (NOD2) with a NOD2 agonist or a culture thereof.
Abstract: The present invention relates to equine amniotic fluid-derived multipotent stem cells (Eaf-MSCs) and a preparation method thereof. More particularly, the present invention relates to equine amniotic fluid-derived multipotent stem cells which exhibit all negative immunological characteristics with respect to the human markers, CD19, CD20, CD28, CD31, CD34, CD38, CD41A, CD62L, CD62P and CD200, and exhibit all positive immunological characteristics with respect to the human markers, CD44, CD90 and CD105, and have the ability to differentiate into ectoderm, mesoderm or endoderm-derived cells.
Type:
Grant
Filed:
September 7, 2011
Date of Patent:
March 22, 2016
Assignee:
KANG STEM BIOTECH CO., LTD.
Inventors:
Kyung Sun Kang, Min Soo Seo, Sang Bum Park